Multidisciplinary Treatment of Merkel Cell Carcinoma of the Extremities: Outcomes and Factors Associated with Poor Survival in Nodal Disease

Author:

Broida Samuel E.1ORCID,Chen Xiao T.1,Wahlig Brian D.1,Moran Steven L.2,Houdek Matthew T.1ORCID

Affiliation:

1. Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA

2. Department of Plastic Surgery, Mayo Clinic, Rochester, MN 55905, USA

Abstract

Merkel cell carcinoma (MCC) has a tendency for lymphatic spread and locoregional recurrence, although there is little data examining the risk factors for patients with lymph node-positive extremity lesions. The purpose of the current study was to examine the outcomes and risk factors associated with nodal metastasis in extremity MCC. We retrospectively reviewed the medical record of 120 patients with extremity MCC evaluated at our institution between 1994 and 2021. The mean age of this cohort was 71 years; 33% of patients were female; and 98% were Caucasian. Seventy-eight (65%) patients presented with localized disease. Thirty-seven (31%) patients had stage III disease, and five (4%) patients had stage IV disease. Treatment of primary lesions consisted primarily of margin-negative excision and adjuvant radiotherapy. Nodal metastases were most treated with adjuvant radiation or completion lymph node dissection. Five-year disease-specific survival in our series was 88% for patients with localized disease, 89% for stage IIIa disease, 40% for stage IIIb disease and 42% for stage IV. Factors associated with worse survival included immunosuppression and macroscopic nodal disease. In conclusion, extremity MCC has a low rate of local recurrence when treated with margin-negative excision and adjuvant radiation. However, treatment of nodal metastases remains a challenge with high rates of recurrence and mortality, particularly for patients who are immunosuppressed or who have macroscopic nodal disease.

Publisher

MDPI AG

Reference21 articles.

1. Merkel cell carcinoma;Becker;Nat. Rev. Dis. Prim.,2017

2. Merkel Cell Carcinoma: Prognosis and Treatment of Patients From a Single Institution;Allen;J. Clin. Oncol.,2005

3. (2022, October 27). Merkel Cell Carcinoma, Version 1.2021, NCCN Clinical Practice Guidelines in Oncology. Available online: https://merkelcell.org/wp-content/uploads/2021/02/NCCN-2021.pdf.

4. Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?;Farley;Ann. Surg. Oncol.,2020

5. Oncologic outcomes of patients with Merkel Cell Carcinoma (MCC): A multi-institutional cohort study;Bleicher;Am. J. Surg.,2020

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3